Please use this identifier to cite or link to this item:
Title: Somatostatin and the 'Small-For-Size' Liver
Author: Hessheimer, Amelia Judith
Martínez de la Maza, Lilia
Adel Al Shwely, Farah
Espinoza, Arlena Sofía
Ausania, Fabio
Fondevila Campo, Constantino
Keywords: Trasplantament hepàtic
Hipertensió portal
Insuficiència hepàtica
Hepatic transplantation
Portal hypertension
Liver failure
Issue Date: 22-May-2019
Publisher: MDPI
Abstract: "Small-for-size" livers arising in the context of liver resection and transplantation are vulnerable to the effects of increased portal flow in the immediate postoperative period. Increased portal flow is an essential stimulus for liver regeneration. If the rise in flow and stimulus for regeneration are excessive; however, liver failure and patient death may result. Somatostatin is an endogenous peptide hormone that may be administered exogenously to not only reduce portal blood flow but also offer direct protection to different cells in the liver. In this review article, we describe key changes that transpire in the liver following a relative size reduction occurring in the context of resection and transplantation and the largely beneficial effects that peri-operative somatostatin therapy may help achieve in this setting.
Note: Reproducció del document publicat a:
It is part of: International Journal of Molecular Sciences, 2019, vol. 20, num. 10, p. 2512
Related resource:
ISSN: 1661-6596
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Files in This Item:
File Description SizeFormat 
695812.pdf1.49 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons